NL1031218A1 - Oxyindoolderivaten. - Google Patents

Oxyindoolderivaten.

Info

Publication number
NL1031218A1
NL1031218A1 NL1031218A NL1031218A NL1031218A1 NL 1031218 A1 NL1031218 A1 NL 1031218A1 NL 1031218 A NL1031218 A NL 1031218A NL 1031218 A NL1031218 A NL 1031218A NL 1031218 A1 NL1031218 A1 NL 1031218A1
Authority
NL
Netherlands
Prior art keywords
oxyindole derivatives
oxyindole
derivatives
Prior art date
Application number
NL1031218A
Other languages
English (en)
Other versions
NL1031218C2 (nl
Inventor
Kiyoshi Kawamura
Hiroki Sone
Chikara Uchida
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NL1031218A1 publication Critical patent/NL1031218A1/nl
Application granted granted Critical
Publication of NL1031218C2 publication Critical patent/NL1031218C2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NL1031218A 2005-02-22 2006-02-22 Oxyindoolderivaten. NL1031218C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65527605P 2005-02-22 2005-02-22
US65527605 2005-02-22

Publications (2)

Publication Number Publication Date
NL1031218A1 true NL1031218A1 (nl) 2006-08-23
NL1031218C2 NL1031218C2 (nl) 2007-01-23

Family

ID=36579484

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1031218A NL1031218C2 (nl) 2005-02-22 2006-02-22 Oxyindoolderivaten.

Country Status (32)

Country Link
US (2) US7589109B2 (nl)
EP (1) EP1856110B1 (nl)
JP (1) JP4130220B1 (nl)
KR (1) KR100908547B1 (nl)
CN (1) CN101522668B (nl)
AP (1) AP2007004067A0 (nl)
AR (1) AR053548A1 (nl)
AT (1) ATE513827T1 (nl)
AU (1) AU2006217534B8 (nl)
BR (1) BRPI0607456A2 (nl)
CA (1) CA2598536C (nl)
DK (1) DK1856110T3 (nl)
DO (1) DOP2006000046A (nl)
EA (1) EA012615B1 (nl)
ES (1) ES2366375T3 (nl)
GE (1) GEP20094727B (nl)
GT (1) GT200600083A (nl)
HK (1) HK1135966A1 (nl)
HN (1) HN2006007884A (nl)
IL (1) IL184505A0 (nl)
MA (1) MA29260B1 (nl)
MX (1) MX2007010139A (nl)
NL (1) NL1031218C2 (nl)
NO (1) NO20073566L (nl)
NZ (1) NZ556627A (nl)
PE (1) PE20061096A1 (nl)
TN (1) TNSN07319A1 (nl)
TW (1) TW200640915A (nl)
UA (1) UA86301C2 (nl)
UY (1) UY29389A1 (nl)
WO (1) WO2006090279A1 (nl)
ZA (1) ZA200706420B (nl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
JP4130220B1 (ja) * 2005-02-22 2008-08-06 ファイザー株式会社 ５ｈｔ４受容体アゴニストとしてのオキシインドール誘導体
AU2006263564A1 (en) * 2005-06-29 2007-01-04 Merck Sharp & Dohme Corp. 4-fluoro-piperidine T-type calcium channel antagonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2007086559A1 (ja) * 2006-01-27 2007-08-02 Ube Industries, Ltd. テトラヒドロピラン化合物の製造方法
US20080051585A1 (en) * 2006-08-17 2008-02-28 Wyeth Process for the preparation of indolin-2-one derivatives useful as PR modulators
WO2009112874A1 (en) * 2008-03-10 2009-09-17 Eurodrug Laboratories B.V. Modified release composition comprising doxofylline
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
CA2750699C (en) * 2009-02-27 2015-12-29 Raqualia Pharma Inc. Oxyindole derivatives with motilin receptor agonistic activity
EP2427054A4 (en) * 2009-05-07 2014-01-15 United Therapeutics Corp SOLID COMPOSITIONS BASED ON PROSTACYCLINE ANALOGS
CN102639526B (zh) 2009-09-14 2014-06-04 苏文生命科学有限公司 作为5-ht4受体配体的1,2-二氢-2-氧代喹啉化合物
MX343165B (es) * 2010-02-12 2016-10-26 Raqualia Pharma Inc Agonistas del receptor 5-ht4 para el tratamiento de demencia.
WO2013042135A1 (en) 2011-09-19 2013-03-28 Suven Life Sciences Limited Heteroaryl compounds as 5-ht4 receptor ligands
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
ES2760261T3 (es) 2014-02-13 2020-05-13 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
SG11201708047UA (en) 2015-04-03 2017-10-30 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
WO2017027678A1 (en) * 2015-08-12 2017-02-16 Incyte Corporation Salts of an lsd1 inhibitor
WO2017141106A1 (en) * 2016-02-16 2017-08-24 Strongbridge Biopharma plc Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia, and hormone-related tumors
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN114105863B (zh) * 2021-12-07 2023-11-28 江苏汉拓光学材料有限公司 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552408A (en) 1987-09-23 1996-09-03 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
JPH06506443A (ja) 1991-01-09 1994-07-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物
US5955470A (en) 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9121170D0 (en) 1991-10-05 1991-11-20 Smithkline Beecham Plc Pharmaceuticals
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5280028A (en) 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5521193A (en) 1992-06-24 1996-05-28 G. D. Searle & Co. Benzimidazole compounds
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
FR2694292B1 (fr) 1992-07-29 1994-10-21 Esteve Labor Dr Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament.
US5705498A (en) 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
TW251287B (nl) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9312348D0 (en) 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
US5534521A (en) 1993-06-23 1996-07-09 G. D. Searle & Co. Benzimidazole compounds
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
GB9414139D0 (en) 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
DE4440675A1 (de) 1994-11-14 1996-05-15 Basf Ag Verfahren zur Herstellung von kautschukmodifizierten Formmassen mittels in den Kautschuk eingebauten, bei thermischer Zersetzung Radikale bildenden Gruppen
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
WO1999012903A1 (en) 1997-09-09 1999-03-18 Du Pont Pharmaceuticals Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6310059B1 (en) 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
AU1707700A (en) 1998-10-29 2000-05-22 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
AU784848B2 (en) 1999-12-20 2006-07-06 Zalicus Pharmaceuticals Ltd. Partially saturated calcium channel blockers
WO2002030886A2 (en) 2000-10-12 2002-04-18 Matthews Barry R Heterocyclic angiogenesis inhibitors
EP1341773A2 (en) 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
EP1637521B1 (en) 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Novel tricyclic heterocycle compound
PL1664036T3 (pl) * 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
JP4130220B1 (ja) * 2005-02-22 2008-08-06 ファイザー株式会社 ５ｈｔ４受容体アゴニストとしてのオキシインドール誘導体

Also Published As

Publication number Publication date
CN101522668B (zh) 2012-06-06
DOP2006000046A (es) 2006-08-31
GEP20094727B (en) 2009-07-10
AU2006217534B2 (en) 2011-08-11
UA86301C2 (en) 2009-04-10
US20060194842A1 (en) 2006-08-31
TW200640915A (en) 2006-12-01
IL184505A0 (en) 2007-10-31
ZA200706420B (en) 2009-04-29
BRPI0607456A2 (pt) 2009-09-08
MX2007010139A (es) 2007-09-27
WO2006090279A1 (en) 2006-08-31
CA2598536A1 (en) 2006-08-31
US20100173925A1 (en) 2010-07-08
CN101522668A (zh) 2009-09-02
CA2598536C (en) 2011-04-05
GT200600083A (es) 2006-11-07
US7589109B2 (en) 2009-09-15
EA200701552A1 (ru) 2007-12-28
ATE513827T1 (de) 2011-07-15
EP1856110A1 (en) 2007-11-21
DK1856110T3 (da) 2011-08-15
HN2006007884A (es) 2010-01-18
NO20073566L (no) 2007-08-08
KR100908547B1 (ko) 2009-07-20
AU2006217534A1 (en) 2006-08-31
KR20070098936A (ko) 2007-10-05
AP2007004067A0 (en) 2007-08-31
JP4130220B1 (ja) 2008-08-06
AR053548A1 (es) 2007-05-09
JP2008531543A (ja) 2008-08-14
TNSN07319A1 (fr) 2008-12-31
NZ556627A (en) 2010-09-30
MA29260B1 (fr) 2008-02-01
PE20061096A1 (es) 2006-11-09
AU2006217534A8 (en) 2011-12-08
UY29389A1 (es) 2006-10-02
NL1031218C2 (nl) 2007-01-23
EP1856110B1 (en) 2011-06-22
HK1135966A1 (en) 2010-06-18
EA012615B1 (ru) 2009-10-30
ES2366375T3 (es) 2011-10-19
AU2006217534B8 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
NL300935I2 (nl) guselkumab.
NL1031218A1 (nl) Oxyindoolderivaten.
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
NO20051199L (no) Rorhandteringsutstyr.
NL2000323A1 (nl) Pyrimidine-derivaten.
DE602006020996D1 (de) Hreren eingängen
NL2000537A1 (nl) Aminederivaten.
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
NL2000284A1 (nl) Pyrazine-derivaten.
ATE537171T1 (de) Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
DK1885966T3 (da) Forbedret hoved-t-forbindelse
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
NL2000336A1 (nl) Spirocyclische derivaten.
NO20053362D0 (no) Syklofuge.
NL1032046A1 (nl) Prostaglandinederivaten.
NL2000937A1 (nl) Piperidinederivaten.
DE602006014973D1 (de) Neuartige cercosporamidderivate
ITMI20050051A1 (it) Fotodiodio organico di poli-9,9-diottil-fluorene
DE502006006589D1 (de) Teils
ATE541837T1 (de) Oxaphenanthren-derivate
DE602006019209D1 (de) Fluoroalkylpyrrolidin-derivate
ES1061250Y (es) Conjunto garrafa-tapon.
ES1059785Y (es) Caja-asiento.

Legal Events

Date Code Title Description
AD1B A search report has been drawn up
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20060918

PD2B A search report has been drawn up
V1 Lapsed because of non-payment of the annual fee

Effective date: 20140901